Join Daniel Soffer, MD, a leading internist and lipid specialist and the immediate past president of the National Lipid Association, as he shares groundbreaking advancements in lipid management from the recent NLA meeting. Discover the importance of measuring patient responses, the benefits of combination therapies, and the latest in drug development for tackling lipid disorders.
Lipid Disorders Management Strategies (2024) in Prediabetic and Diabetic Patients
Source : https://pubmed.ncbi.nlm.nih.gov/38399434/
Dyslipidaemia is a modifiable risk factor commonly associated with diabetes mellitus and prediabetes, with a major impact on the early development of atherosclerotic cardiovascular disease. Various studies have tried to...
Dyslipidaemia in diabetes and prediabetes contributes to early atherosclerosis. This review summarizes current lipid disorder treatments and guideline recommendations for managing dyslipidaemia with various pharmacologic options.
Unveiling Familial Hypercholesterolemia-Review, Cardiovascular Complications, Lipid-Lowering Treatment and Its Efficacy
Source : https://pubmed.ncbi.nlm.nih.gov/38338916/
Familial hypercholesterolemia (FH) is a genetic disorder primarily transmitted in an autosomal-dominant manner. We distinguish two main forms of FH, which differ in the severity of the disease, namely homozygous...
Familial hypercholesterolemia (FH) is an autosomal-dominant genetic disorder causing high LDL-C levels, leading to premature cardiovascular disease. This review evaluates lipid-lowering therapies and FH's link to early CVD.
C3G and Ig-MPGN-treatment standard
Source : https://pubmed.ncbi.nlm.nih.gov/37604793/
Among the broad spectrum of membranoproliferative glomerulonephritis (MPGN), immunofluorescence distinguishes C3 glomerulopathy (C3G), with predominant C3 deposits, and immunoglobulin-associated MPGN (Ig-MPGN), with combined C3 and Ig. However, there are several...
Accurate diagnosis and targeted therapies for primary C3G and Ig-MPGN may improve outcomes through unsupervised clustering analysis and ongoing complement cascade-targeting trials.
Traditional and novel non-statin lipid-lowering drugs
Source : https://pubmed.ncbi.nlm.nih.gov/37979722/
Non-statin drugs find utility in the management of dyslipidaemia in mixed dyslipidaemia, patients with statin intolerance, and when guidelines directed low-density lipoprotein cholesterol (LDL-C) target cannot be achieved despite maximally...
Non-statin drugs are crucial for managing dyslipidaemia in specific patient groups, especially when LDL-C targets are unachievable with statins alone or in cases of statin intolerance.
Effects of Dietary Carbohydrate Concentration and Glycemic Index on Blood Glucose Variability and Free Fatty Acids in Individuals with Type 1 Diabetes
Source : https://pubmed.ncbi.nlm.nih.gov/38732629/
Monitoring glycemic control status is the cornerstone of diabetes management. This study aimed to reveal whether moderate-carbohydrate (CHO) diets increase the risk of free fatty acid (FFA) levels, and it...
In type 1 diabetes, moderate-carbohydrate diets, regardless of glycemic index, did not significantly impact glycemic control but increased free fatty acid and triglyceride levels, potentially elevating cardiovascular risk.
Modulating the Gut Microbiota and Metabolites with Traditional Chinese Medicines: An Emerging Therapy for Type 2 Diabetes Mellitus and Its Complications
Source : https://pubmed.ncbi.nlm.nih.gov/38930814/
Currently, an estimated 537 million individuals are affected by type 2 diabetes mellitus (T2DM), the occurrence of which is invariably associated with complications. Glucose-lowering therapy remains the main treatment for...
Traditional Chinese medicines (TCMs) modulate gut microbiota, restoring host homeostasis and ameliorating metabolic disorders, offering a promising approach for managing type 2 diabetes mellitus and its complications with fewer adverse effects.
Comparing the Efficacy of Digital and In-Person Weight Loss Interventions for Patients with Obesity and Glycemic Disorders: Evidence from a Randomized Non-Inferiority Trial
Source : https://pubmed.ncbi.nlm.nih.gov/38794747/
Digital weight loss interventions present a viable and cost-effective alternative to traditional therapy. However, further evidence is needed to establish the equal effectiveness of both approaches. This randomized controlled non-inferiority...
Vitadio digital therapy is an effective alternative to traditional in-person weight loss programs, demonstrating comparable weight reduction, improved body composition, lipid metabolism, and glycemic control in patients with obesity.
Dapagliflozin added to metformin reduces perirenal fat layer in type 2 diabetic patients with obesity
Source : https://pubmed.ncbi.nlm.nih.gov/38734755/
Sodium-glucose co-transporters type 2 inhibitors (SLGT2i) are highly effective in controlling type 2 diabetes, but reported beneficial cardiovascular effects suggest broader actions on insulin resistance. Weight loss may be initially...
Both metformin and dapagliflozin effectively reduce abdominal fat in type 2 diabetes patients, with combined treatment particularly targeting perirenal fat, suggesting enhanced cardiovascular benefits of dapagliflozin.
Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines
Source : https://pubmed.ncbi.nlm.nih.gov/38163998/
The evidence supporting the use of inositol in the management of PCOS is limited and inconclusive. Clinicians and their patients should consider the uncertainty of the evidence together with individual...
The evidence supporting the use of inositol in the management of PCOS is limited and inconclusive. Clinicians and their patients should consider the uncertainty of the evidence together with individual values and preferences when engaging in shared decision-making regarding the use of inositol for PCOS.
Lipid Association of India 2023 update on cardiovascular risk assessment and lipid management in Indian patients: Consensus statement IV
Source : https://pubmed.ncbi.nlm.nih.gov/38485619/
This document presents the updated risk stratification and treatment algorithm and describes the rationale for each modification. The intent of these updated recommendations is to modernize management of dyslipidemia in...
Updated risk stratification and treatment algorithm and describes the rationale for each modification. The intent of these updated recommendations is to modernize management of dyslipidemia in Indian patients with the goal of reducing the epidemic of ASCVD among Indians in Asia and worldwide.
Unique features of dyslipidemia in women across a lifetime and a tailored approach to management
Source : https://pubmed.ncbi.nlm.nih.gov/38634109/
Pathophysiology of dyslipidemia varies between men and women and across a woman's lifetime. While increased lipid levels or lipid imbalances are more common in postmenopausal women over age 50, conditions...
Managing dyslipidemia in women involves early screening, lifestyle changes, and pharmacotherapy tailored to achieve guideline-directed LDL-C levels, addressing risks across different life stages and conditions like PCOS and FH.
Lipid-based eye drop formulations for the management of evaporative dry eyes
Source : https://pubmed.ncbi.nlm.nih.gov/38523013/
Dry eye disease is a progressive prevalent ocular surface disorder that arises from various factors and is characterized by insufficient quality and/or quantity of tears. The underlying pathophysiology is intricate...
Lipid-based eye drops show potential for treating evaporative dry eyes, but further placebo-controlled trials and innovations are needed to optimize formulations and effectiveness in replicating natural tear lipids.
Lipid-lowering in diabetes: An update
Source : https://pubmed.ncbi.nlm.nih.gov/37945448/
Atherosclerotic cardiovascular disease (ASCVD) is accelerated in people with diabetes. Dyslipidemia, hyperglycemia, oxidative stress, and inflammation play a role via a variety of mechanisms operative in the artery wall. In...
Effective management of dyslipidemia in T2DM patients is crucial to prevent ASCVD, focusing on significant LDL-C reduction and comprehensive lowering of apo B-containing lipoproteins. Emerging therapies, including ASO and RNA-based treatments, offer additional cardiovascular benefits.
New Insights Into the Treatment of Hyperlipidemia: Pharmacological Updates and Emerging Treatments
Source : https://pubmed.ncbi.nlm.nih.gov/38919858/
Cardiovascular diseases are the leading causes of global mortality and morbidity. Hyperlipidemia is a significant risk factor for atherosclerosis and subsequent cardiovascular diseases. Hyperlipidemia is characterized by imbalances in blood...
Hyperlipidemia, influenced by genetics and lifestyle, is a key modifiable risk factor for cardiovascular diseases. Effective management involves lifestyle changes, traditional medications like statins, and emerging therapies such as PCSK9 inhibitors and inclisiran. Advances in genetic research and personalized medicine are enhancing...
Osteoprotegerin mediates adipogenesis in obesity
Source : https://pubmed.ncbi.nlm.nih.gov/38906326/
OPG emerges as a key regulator in mediating adipogenesis during obesity development. Targeting OPG holds promise for the prevention and treatment of obesity, as evidenced by the efficacy of electroacupuncture...
OPG emerges as a key regulator in mediating adipogenesis during obesity development. Targeting OPG holds promise for the prevention and treatment of obesity, as evidenced by the efficacy of electroacupuncture treatment in modulating OPG levels and managing obesity-related outcomes.
Breaking new ground in lipid management: Insights from the 2024 American College of Cardiology Scientific Sessions
Source : https://pubmed.ncbi.nlm.nih.gov/38849020/
Breaking new ground in lipid management: Insights from the 2024 American College of Cardiology Scientific Sessions
The recent ACC meeting in Atlanta has underscored a transformative surge in the field of lipid disorders, positioning it as a rapidly advancing frontier in contemporary medicine. This pivotal moment represents a critical call to action, challenging us to address the widespread public unawareness that permeates this dominant health risk.
Genetically predicted lipids mediate the association between intrahepatic cholestasis of pregnancy and cardiovascular disease
Source : https://pubmed.ncbi.nlm.nih.gov/38745758/
The results underscore the genetic predisposition of ICP to elevate CVD risk and the critical mediating role of lipid levels, emphasizing the need for vigilant lipid monitoring and early intervention...
The results underscore the genetic predisposition of ICP to elevate CVD risk and the critical mediating role of lipid levels, emphasizing the need for vigilant lipid monitoring and early intervention in individuals with ICP.
This study suggests that because there is a substantial range of values of apoB for any value of LDL-C or non–HDL-C, restricting testing of apoB to those with metabolic risk factors will miss a substantial minority of individuals with discordantly elevated levels of apoB relative to LDL-C or non–HDL-C.
Use of lipid ratios to predict vascular target organ damage in youth
Source : https://pubmed.ncbi.nlm.nih.gov/38462388/
Arterial stiffness is increased in youth with high lipid ratios with TG/HDL-C being the most consistent marker of vascular changes. These data suggest that identification of high TG/HDL-C in these...
Arterial stiffness is increased in youth with high lipid ratios with TG/HDL-C being the most consistent marker of vascular changes. These data suggest that identification of high TG/HDL-C in these individuals may lead to earlier intervention to prevent atherosclerotic cardiovascular disease.